Maintain Elahere access for ovarian cancer patients

 
Join 1 people who have already added their signatures to this Open Letter.  Please add you name today and help us reach 100 signatures.
 
 
 
To:
  • Secretary of State for Health and Social Care
  • Vice President and General Manager of AbbVie UK (pharmaceutical company responsible for Elahere)
 
 
Dear Sirs
 
We were dismayed to learn of the recent announcement by the National Institue for Health and Care Excellence (NICE) that they will not be recommending mirevtuximab soravtansine (Elahere) for routine commissioning within the NHS in England. 
 
As you know, NICE acknowledges that Elahere offers both clinical benefits and the prospect of improved quality of life for women with platinum resistant ovarian cancer.  The NICE decision has been taken purely on the grounds of cost effectiveness.

We passionately believe that patients with ovarian cancer should have access to the best possible treatment targeted to their needs. We therefore call on NHS England, the Department for Health and Social Care and AbbVie, the manufacturer of Elahere, to urgently reopen discussions with one another, to find a solution that ensures women are able to access this vital treatment.

As you will know, ovarian cancer is a devastating disease and women with the platinum resistant form have very limited treatment options.  Those that have received this innovative treatment during clinical trials have reported significant benefits. It would be deeply disappointing if future ovarian cancer patients were not given the option of this treatment simply because NHS England, DHSC and AbbVie were unable to resolve disagreements on price.

Please give hope to women who will be diagnosed with platinum resistant ovarian cancer: please return to the negotiating table.

 
Yours faithfully
 

 
 
Please answer both questions below.
Want to be kept updated by email on our work, campaigns, fundraising activities, events, services and volunteering opportunities?  If you already hear from us and wish to continue, please tick yes.


 
 
Tell us more about yourself so we can make sure our communications are relevant to you.
We will never sell your data and promise to keep it safe and secure.  You can change your preferences at any time.  For further details on how your data is used and stored please see our privacy notice, or telephone us on 020 7923 5470.
Data will be processed by Organic Campaigns: Privacy policy. Acknowledgements